<?xml version="1.0" encoding="UTF-8"?>
<p>Vaccination against EV71 was initiated in 2015 in China [
 <xref rid="pone.0217474.ref030" ref-type="bibr">30</xref>], which might be expected to reduce the fatality rate of HFMD because over 80% of severe cases and 90% of deaths of HFMD were from EV71 infections[
 <xref rid="pone.0217474.ref003" ref-type="bibr">3</xref>]. However, EV71 only accounted for 30.1% in our study, similar to neighboring Chongqing with 25.1% [
 <xref rid="pone.0217474.ref002" ref-type="bibr">2</xref>]. Since the inactivated monovalent EV71 vaccines offer no protection against HFMD caused by CV-A16 and CV-A6 and CV-A10 are emerging as prominent new serotypes among the classification of other EVs [
 <xref rid="pone.0217474.ref007" ref-type="bibr">7</xref>, 
 <xref rid="pone.0217474.ref008" ref-type="bibr">8</xref>, 
 <xref rid="pone.0217474.ref026" ref-type="bibr">26</xref>, 
 <xref rid="pone.0217474.ref031" ref-type="bibr">31</xref>](20/42, CV-A6; and 14/42 CV-A10 by subtyping from Neijiang city), the polyvalent vaccine against the HFMD virus would be urgently needed to enlarge the coverage range protected by vaccinations.
</p>
